跳至主要内容
临床试验/NCT00038948
NCT00038948已完成3 期

A Randomized, Open-label, Comparative Evaluation of Conversion From Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients

Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 830 人开始时间: 2002年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
830
主要终点
Nankivell Glomerular Filtration Rate (GFR)

研究概览

简要总结

The purpose of this study is to determine the effect of conversion from calcineurin inhibitor to sirolimus based therapy on renal function.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
13 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age greater than or equal to 13 years.
  • Receiving CsA or tacrolimus from the time of transplantation or within 2 weeks thereafter
  • Patients with a functioning allograft and a Nankivell GFR greater than or equal to 20 mL/min, within 2 weeks before randomization

排除标准

  • Biopsy-confirmed acute rejection within 12 weeks before randomization, that was determined to require antirejection treatment
  • Patients in whom kidney-pancreas or other multiple organ transplants have been performed

研究组 & 干预措施

A

Active Comparator

Conversion from calcineurin inhibitor immunosuppression to Sirolimus-based immunosuppression

干预措施: Sirolimus (Drug)

A

Active Comparator

Conversion from calcineurin inhibitor immunosuppression to Sirolimus-based immunosuppression

干预措施: tacrolimus (Drug)

A

Active Comparator

Conversion from calcineurin inhibitor immunosuppression to Sirolimus-based immunosuppression

干预措施: Cyclosporine A (Drug)

B

Active Comparator

Continued calcineurin inhibitor therapy

干预措施: Sirolimus (Drug)

B

Active Comparator

Continued calcineurin inhibitor therapy

干预措施: tacrolimus (Drug)

B

Active Comparator

Continued calcineurin inhibitor therapy

干预措施: Cyclosporine A (Drug)

结局指标

主要结局

Nankivell Glomerular Filtration Rate (GFR)

时间窗: 52 weeks

Nankivell GFR: patients with baseline GFR of 20.0 to 40.0 mL/min and patients with baseline GFR of greater than 40.0 mL/min. GFR is an index of kidney function. A higher value means better kidney function.

次要结局

  • First Occurrence of Biopsy-confirmed Acute Rejection, Graft Loss, or Death.(52 and 104 weeks)

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry

相似试验